
    
      CX-839-007 is an open-label Phase 2 study of the combination of CB-839 with paclitaxel in
      patients of African ancestry and non-African ancestry with advanced triple negative breast
      cancer. Multiple single-arm cohorts will be enrolled in which 800 mg BID CB-839 will be
      administered in combination with the full approved dose of paclitaxel.

      Patients will be enrolled into 4 cohorts, as follows:

        -  Cohort 1: patients of African ancestry with 2 or more lines of prior therapy for
           metastatic disease

        -  Cohort 2: patients of African ancestry with no prior lines of therapy for metastatic
           disease

        -  Cohort 3: same as cohort 1 but in patients of non-African ancestry

        -  Cohort 4: same as cohort 2 but in patients of non-African ancestry
    
  